JP2005513416A5 - - Google Patents

Download PDF

Info

Publication number
JP2005513416A5
JP2005513416A5 JP2003525032A JP2003525032A JP2005513416A5 JP 2005513416 A5 JP2005513416 A5 JP 2005513416A5 JP 2003525032 A JP2003525032 A JP 2003525032A JP 2003525032 A JP2003525032 A JP 2003525032A JP 2005513416 A5 JP2005513416 A5 JP 2005513416A5
Authority
JP
Japan
Prior art keywords
receptor
amino acid
acid sequence
proline
sequence shown
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2003525032A
Other languages
Japanese (ja)
Other versions
JP4467973B2 (en
JP2005513416A (en
Filing date
Publication date
Priority claimed from AUPR7431A external-priority patent/AUPR743101A0/en
Priority claimed from AUPR7430A external-priority patent/AUPR743001A0/en
Priority claimed from PCT/AU2002/000061 external-priority patent/WO2002057306A1/en
Application filed filed Critical
Priority claimed from PCT/AU2002/001204 external-priority patent/WO2003020762A1/en
Publication of JP2005513416A publication Critical patent/JP2005513416A/en
Publication of JP2005513416A5 publication Critical patent/JP2005513416A5/ja
Application granted granted Critical
Publication of JP4467973B2 publication Critical patent/JP4467973B2/en
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Claims (30)

単離されたＰ２Ｘ７リセプターであって、An isolated P2X7 receptor,
− 図１に示す配列と類似性を有するアミノ酸配列を有し、Having an amino acid sequence similar to the sequence shown in FIG.
− 前記単離されたＰ２Ｘ７リセプターのアミノ酸配列は、図１に示すプロリン２１０に対応するプロリンを含み、前記プロリンはシスコンフォメーションにある、単離されたＰ２Ｘ７リセプター。-The isolated P2X7 receptor, wherein the amino acid sequence of the isolated P2X7 receptor comprises a proline corresponding to proline 210 shown in Fig. 1, wherein the proline is in cis conformation. 前記リセプターがげっ歯類のリセプターである、請求項１に記載のリセプター。The receptor of claim 1, wherein the receptor is a rodent receptor. 前記リセプターがマウス、ラット、又はウサギのリセプターである、請求項２に記載のリセプター。The receptor according to claim 2, wherein the receptor is a mouse, rat, or rabbit receptor. ２１０位のプロリンがシスコンフォメーションにある、図１に示すアミノ酸配列を有する単離されたＰ２Ｘ７リセプター。An isolated P2X7 receptor having the amino acid sequence shown in FIG. 1, wherein the proline at position 210 is in cis conformation. − 請求項１に記載のリセプター；又はThe receptor according to claim 1; or
− シスコンフォメーションにある２１０位のプロリンを含む、前記リセプターの断片のアミノ酸配列を有するペプチド；-A peptide having the amino acid sequence of said receptor fragment, comprising proline at position 210 in cis conformation;
の、病気又は症状の予防又は治療のためのワクチンの製造における使用。In the manufacture of a vaccine for the prevention or treatment of a disease or condition. − 請求項１に記載のＰ２Ｘ７リセプター；又はA P2X7 receptor according to claim 1; or
− シスコンフォメーションにある２１０位のプロリンを含む、前記リセプターの断片のアミノ酸配列を有するペプチド；-A peptide having the amino acid sequence of said receptor fragment, comprising proline at position 210 in cis conformation;
を含む、病気又は症状の予防又は治療のためのワクチン。A vaccine for the prevention or treatment of illness or symptoms. 前記リセプター又はペプチドがキャリアーに接合されている、請求項６に記載のワクチン。The vaccine of claim 6, wherein the receptor or peptide is conjugated to a carrier. 前記キャリアーがジフテリアトキシンである、請求項７に記載のワクチン。The vaccine according to claim 7, wherein the carrier is diphtheria toxin. アジュバントを更に含む、請求項６から８のいずれか一項に記載のワクチン。The vaccine according to any one of claims 6 to 8, further comprising an adjuvant. 前記アジュバントがクイルＡ／ＤＥＡＥ デクストラン／モンタニドを含む、請求項９に記載のワクチン。10. The vaccine of claim 9, wherein the adjuvant comprises quill A / DEAE dextran / montanide. − 請求項６から１０のいずれか一項に記載のワクチンを提供して、患者の病気又は症状を治療するか又は患者の病気又は症状を予防する工程-Providing the vaccine according to any one of claims 6 to 10 to treat or prevent a disease or condition of a patient;
を含む、患者の病気又は症状を治療又は予防するための方法。A method for treating or preventing a disease or condition in a patient, comprising: 前記病気が癌である、請求項１１に記載の方法。The method of claim 11, wherein the disease is cancer. 前記癌が、前立腺、乳、皮膚、肺、頸部、子宮、胃、食道、膀胱、結腸、膣、及び血液の癌、並びに悪性リンパ腫からなる群から選択される、請求項１２に記載の方法。13. The method of claim 12, wherein the cancer is selected from the group consisting of prostate, breast, skin, lung, cervix, uterus, stomach, esophagus, bladder, colon, vagina, and blood cancer, and malignant lymphoma. . ２１０位のプロリンがシスコンフォメーションにある図１に示すアミノ酸配列を有するＰ２Ｘ７リセプターの細胞外領域に結合し、２１０位のプロリンがトランスコンフォメーションにある図１に示すアミノ酸配列を有するＰ２Ｘ７リセプターの細胞外領域に結合しない、ヒツジ、ウサギ、マウス、又はラットの抗体。The proline at position 210 binds to the extracellular region of the P2X7 receptor having the amino acid sequence shown in FIG. 1 in the cis-conformation, and the extracellular region of the P2X7 receptor having the amino acid sequence shown in FIG. Sheep, rabbit, mouse, or rat antibody that does not bind to the region. − ２１０位のプロリンがシスコンフォメーションにある図１に示すアミノ酸配列を有するＰ２Ｘ７リセプターの細胞外領域に結合し、２１０位のプロリンがトランスコンフォメーションにある図１に示すアミノ酸配列を有するＰ２Ｘ７リセプターの細胞外領域に結合しない抗体A cell of P2X7 receptor having the amino acid sequence shown in FIG. 1 that binds to the extracellular region of the P2X7 receptor having the amino acid sequence shown in FIG. 1 in which the proline at position 210 is in cis conformation. Antibodies that do not bind to the outer region
の、病気又は症状の予防又は治療のための皮膚への適用のために調製される組成物の製造における使用。In the manufacture of a composition prepared for application to the skin for the prevention or treatment of a disease or condition. ２１０位のプロリンがシスコンフォメーションにある図１に示すアミノ酸配列を有するＰ２Ｘ７リセプターの細胞外領域に結合し、２１０位のプロリンがトランスコンフォメーションにある図１に示すアミノ酸配列を有するＰ２Ｘ７リセプターの細胞外領域に結合しない抗体を含む、皮膚への適用のために調製される組成物。The proline at position 210 binds to the extracellular region of the P2X7 receptor having the amino acid sequence shown in FIG. 1 in the cis-conformation, and the extracellular region of the P2X7 receptor having the amino acid sequence shown in FIG. A composition prepared for application to the skin comprising an antibody that does not bind to the area. 前記抗体がヒツジの抗体である、請求項１６に記載の組成物。17. The composition of claim 16, wherein the antibody is a sheep antibody. 前記抗体の皮膚への浸入を促進する化合物を更に含む、請求項１６又は１７に記載の組成物。18. A composition according to claim 16 or 17, further comprising a compound that promotes penetration of the antibody into the skin. 皮膚に潤いを与えるための化合物を更に含む、請求項１６から１８のいずれか一項に記載の組成物。19. A composition according to any one of claims 16 to 18 further comprising a compound for moisturizing the skin. 前記皮膚に潤いを与える化合物がジメチコンである、請求項１９に記載の組成物。20. The composition of claim 19, wherein the skin moisturizing compound is dimethicone. 前記組成物が、クリーム、ローション、軟膏、ゲル、エアロゾル、又はスプレーとして調製される、請求項１６から２０のいずれか一項に記載の組成物。21. A composition according to any one of claims 16 to 20, wherein the composition is prepared as a cream, lotion, ointment, gel, aerosol or spray. 請求項１６から２１のいずれか一項に記載の組成物を提供して、患者の病気又は症状を治療するか又は患者の病気又は症状を予防する工程A step of providing a composition according to any one of claims 16 to 21 to treat or prevent a patient's disease or condition.
を含む、患者の病気又は症状を治療又は予防するための方法。A method for treating or preventing a disease or condition in a patient, comprising: 前記病気又は疾患が皮膚癌である、請求項２２に記載の方法。23. The method of claim 22, wherein the disease or disorder is skin cancer. 前記皮膚癌が、基底細胞癌、扁平上皮細胞癌、悪性黒色腫、及び形成異常班からなる群から選択される、請求項２３に記載の方法。24. The method of claim 23, wherein the skin cancer is selected from the group consisting of basal cell carcinoma, squamous cell carcinoma, malignant melanoma, and dysplasia. − ２１０位のプロリンがシスコンフォメーションにある図１に示すアミノ酸配列を有するＰ２Ｘ７リセプターの細胞外領域に結合し、２１０位のプロリンがトランスコンフォメーションにある図１に示すアミノ酸配列を有するＰ２Ｘ７リセプターの細胞外領域に結合しない抗体A cell of P2X7 receptor having the amino acid sequence shown in FIG. 1 that binds to the extracellular region of the P2X7 receptor having the amino acid sequence shown in FIG. 1 in which the proline at position 210 is in cis conformation. Antibodies that do not bind to the outer region
のｉｎ ｖｉｖｏイメージ技術によって病気又は症状を検知するために適切な試薬の製造における使用。In the manufacture of reagents suitable for detecting diseases or symptoms by in vivo imaging technology. 前記ｉｎ ｖｉｖｏイメージ技術が陽電子放射断層撮影法である、請求項２５に記載の使用。26. Use according to claim 25, wherein the in vivo imaging technique is positron emission tomography. ２１０位のプロリンがシスコンフォメーションにある図１に示すアミノ酸配列を有するＰ２Ｘ７リセプターの細胞外領域に結合し、２１０位のプロリンがトランスコンフォメーションにある図１に示すアミノ酸配列を有するＰ２Ｘ７リセプターの細胞外領域に結合しない抗体を、患者の細胞又は組織と接触させる工程；及びThe proline at position 210 binds to the extracellular region of the P2X7 receptor having the amino acid sequence shown in FIG. 1 in the cis-conformation, and the extracellular region of the P2X7 receptor having the amino acid sequence shown in FIG. Contacting an antibody that does not bind to the region with the patient's cells or tissue; and
前記細胞又は組織が、前記抗体によって結合されるか否かを測定する工程Measuring whether or not the cell or tissue is bound by the antibody
を含む、患者が病気又は症状を有するか否かを診断する方法。A method for diagnosing whether a patient has a disease or symptom. 前記患者の細胞又は組織をｉｎ ｖｉｖｏで抗体と接触させる、請求項２７に記載の方法。28. The method of claim 27, wherein the patient's cells or tissue are contacted with the antibody in vivo. 前記病気又は症状が癌である、請求項２７又は２８に記載の方法。29. A method according to claim 27 or 28, wherein the disease or condition is cancer. 前記癌が、前立腺、乳、皮膚、肺、頸部、子宮、胃、食道、膀胱、結腸、膣、及び血液の癌、並びに悪性リンパ腫から選択される、請求項２９に記載の方法。30. The method of claim 29, wherein the cancer is selected from prostate, breast, skin, lung, cervical, uterus, stomach, esophagus, bladder, colon, vagina, and blood cancers, and malignant lymphomas.
JP2003525032A 2001-09-03 2002-09-03 Diagnosis and treatment of antibodies, cancer and other symptoms corresponding to non-functional P2X7 receptor Expired - Lifetime JP4467973B2 (en)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
AUPR7431 2001-09-03
AUPR7431A AUPR743101A0 (en) 2001-09-03 2001-09-03 A cancer therapeutic
AUPR7430A AUPR743001A0 (en) 2001-09-03 2001-09-03 Diagnosis and treatment of irritable bowel syndrome
AUPR7430 2001-09-03
AUPCT/AU02/00061 2002-01-17
PCT/AU2002/000061 WO2002057306A1 (en) 2001-01-17 2002-01-17 Antibodies to non-functional p2x7 receptor diagnosis and treatment of cancers and other conditions
PCT/AU2002/001204 WO2003020762A1 (en) 2001-09-03 2002-09-03 Antibodies to non-functional p2x7receptor, diagnosis and treatment of cancers and other conditions

Publications (3)

Publication Number Publication Date
JP2005513416A JP2005513416A (en) 2005-05-12
JP2005513416A5 true JP2005513416A5 (en) 2008-05-15
JP4467973B2 JP4467973B2 (en) 2010-05-26

Family

ID=41706691

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2003525032A Expired - Lifetime JP4467973B2 (en) 2001-09-03 2002-09-03 Diagnosis and treatment of antibodies, cancer and other symptoms corresponding to non-functional P2X7 receptor

Country Status (9)

Country Link
JP (1) JP4467973B2 (en)
CN (2) CN100497386C (en)
AU (1) AU2002322192B2 (en)
CA (1) CA2459348C (en)
MY (1) MY142283A (en)
NZ (2) NZ565994A (en)
TW (1) TWI329648B (en)
WO (1) WO2003020762A1 (en)
ZA (1) ZA200402630B (en)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1961767B1 (en) 2001-01-17 2012-03-07 Biosceptre International Limited Diagnosis and treatment of cancers and other conditions
WO2004053426A1 (en) * 2002-12-05 2004-06-24 Kla-Tencor Technologies Corporation Apparatus and methods for detecting overlay errors using scatterometry
US7344860B2 (en) 2003-04-03 2008-03-18 Bristol-Myers Squibb Company Polynucleotide encoding a novel human P2X7 splice variant, HBMYP2X7v
US8124730B1 (en) 2004-04-02 2012-02-28 Bristol-Myers Squibb Company Polynucleotide encoding a novel human P2X7 splice variant, HBMYP2X7v
US7767789B2 (en) * 2005-06-02 2010-08-03 University Hopitals of Cleveland Truncated proteins as cancer markers
US20100036101A1 (en) * 2006-10-10 2010-02-11 Angus Gidley-Baird Antibodies against non functional p2x7 receptor
US8067550B2 (en) * 2006-10-10 2011-11-29 Biosceptre International Limited Hybridomas producing antibodies against non functional P2X7 receptor
NZ583894A (en) 2007-09-14 2013-01-25 Biosceptre Int Ltd Antibodies that bind to a non atp binding p2x7 receptor
AU2013238152B2 (en) * 2007-09-14 2015-09-24 Biosceptre International Limited Purinergic (P2X) receptors in extra-cellular body fluid
AU2008299594B2 (en) 2007-09-14 2013-10-03 Biosceptre International Limited Purinergic (P2X) receptors in extra-cellular body fluid
US8597643B2 (en) * 2008-07-04 2013-12-03 Biosceptre International Limited Antibodies for binding to non-functional P2X7 receptors in trimeric form
CN101469352B (en) * 2008-08-29 2011-12-21 苏州福英基因科技有限公司 In situ hybridization detection kit for early uterocarcinoma
EP3395832B1 (en) * 2009-08-20 2021-11-24 Biosceptre (Aust) Pty Ltd Anti p2x7 receptor antibodies and fragments thereof
CA2784345C (en) 2009-12-24 2018-11-13 Julian Alexander Barden Antibodies to non-functional oligomeric p2x7 receptors
WO2012031333A1 (en) 2010-09-10 2012-03-15 Biosceptre International Limited Companion animal treatments
CN103702683B (en) 2011-07-01 2017-07-04 生物权威(澳大利亚)有限责任公司 Therapeutic alliance
EP2990800A1 (en) * 2014-08-29 2016-03-02 Fundació Institut d'Investigació en Ciències de la Salut Germans Trias i Pujol Neprilysin as heartfailure (HF) prognostic marker
CN114891116A (en) 2015-09-11 2022-08-12 生物权威（英国）有限公司 Chimeric antigen receptor and uses thereof
EP3528789A4 (en) * 2016-10-21 2020-06-24 Biosceptre UK Limited Cytotoxic particles
CN110054691B (en) * 2019-05-09 2021-09-07 潍坊医学院 Hybridoma cell line of anti-human P2RX7 monoclonal antibody

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6133434A (en) * 1997-04-28 2000-10-17 Glaxo Group Limited Purinergic receptor
EP1961767B1 (en) * 2001-01-17 2012-03-07 Biosceptre International Limited Diagnosis and treatment of cancers and other conditions

Similar Documents

Publication Publication Date Title
JP2005513416A5 (en)
Kularatne et al. Evaluation of novel prostate-specific membrane antigen-targeted near-infrared imaging agent for fluorescence-guided surgery of prostate cancer
CN101555283B (en) Antibodies to non-functional p2x7 receptor, diagnosis and treatment of cancers and other conditions
Muanza et al. Evaluation of radiation-induced oral mucositis by optical coherence tomography
BR112020000766A2 (en) anti-cd166 antibodies and their uses
Gao et al. A near-infrared phthalocyanine dye-labeled agent for integrin αvβ6-targeted theranostics of pancreatic cancer
JP4467973B2 (en) Diagnosis and treatment of antibodies, cancer and other symptoms corresponding to non-functional P2X7 receptor
CN105764925A (en) Anti-EpCAM antibodies and methods of use
RU2013123792A (en) COMPOSITIONS AIMED AT THE SOLUBLE EXTRACELLULAR DOMAIN OF E-CADGERIN AND RELATED METHODS FOR TREATING ONCOLOGICAL DISEASES
Bernhard et al. Near infrared fluorescence imaging of EGFR expression in vivo using IRDye800CW-nimotuzumab
Hirner et al. Blastic Plasmacytoid Dendritic Cell Neoplasm
Hartimath et al. Therapeutic potential of nimotuzumab PEGylated-maytansine antibody drug conjugates against EGFR positive xenograft
Chen et al. Detection of Barrett’s neoplasia with a near-infrared fluorescent heterodimeric peptide
EP3979983A1 (en) Liquid botulinum toxin composition for treating moderate to very severe glabellar lines and lateral canthal lines
Sputa‐Grzegrzolka et al. Laugier‐Hunziker syndrome: a case report of the pediatric patient and review of the literature
DE60029953D1 (en) SPECIFIC ANTIBODIES TO HUMAN CHORIONGONADOTROPIN HORMONE AND THEIR USE IN THERAPY AND DIAGNOSIS
CN103432585A (en) Targeted marking system for efficiently mediating folate receptor-alpha subtype
Wang et al. Multiple tiny ectopic sebaceous glands discovered throughout entire esophageal tract
Kilpi et al. The expression of c‐erbB‐2 protein in the keratinocytes of oral mucosal lichen planus
Koo et al. Ornithine decarboxylase levels in the rectal mucosa of patients with colonic neoplasia
Meyer et al. Elevation of CA 19-9 in giant hydronephrosis induced by a renal calculus
Talwar et al. Immunotherapy of advanced stage, invariably drug-resistant cancers expressing ectopically hCG
CN114452409B (en) Near infrared fluorescent imaging agent targeting c-Met and application thereof
Pronin et al. BMJ Open News
WO2020237491A1 (en) Composition and methods to treat ectodermal dysplasia 2, clouston type